US Drug Pricing (Part 2)
Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation jcm9144@gmail.com
SPECIAL REPORT #41
US Drug Pricing (Part 2)
Healthcare costs containment and particularly drug pricing is becoming a major issue in all countries. Although the costs of drugs only represent five to seven percent of overall healthcare costs, prescription drug prices have increased at a faster pace than other healthcare related expenses. One of the main underlying reason of this comes from the recent approval and the worldwide launch of many new specialty care treatments such as oncology and rare diseases.
To illustrate the point, we wish to focus on the recent US FDA approval, since October 21, of five new drugs all with list prices of more than $100,000 per year. Before discounts, Trikafta, a new treatment for patients with the most common cystic fibrosis mutation, will cost $311,503 annually, Brukinsa, a drug developed in China for the treatment of patients with mantle cell lymphoma will cost $12,935 for a 30-day supply, Adakveo, a treatment for sickle cell disease treatment, will cost between $7,000 and 9,500 per month ($84,000 to 114,000 per year), Oxbryta, another sickle cell drug, will be priced at $125,000 per year and finally Givlaari, for acute hepatic porphyria (AHP), will come at a price of $575,000 per year.
For the Biopharmaceutical industry this type of product represents a major new source of revenue. For patients, that means better treatment, longer survival and in some cases a potential cure. But all these treatments come at a very high price for most patients and in some dramatic cases they may trigger personal bankruptcy.
In October 2018, a group of US researchers published in The American Journal of Medicine a study aiming at evaluating the impact of cancer upon a patient’s net worth and debt. The results of the 9.5 million patients they reviewed over the 1998-2014 period are striking. Within two years of diagnosis of the disease 42% of cancer patients exhaust their savings. After four years of therapy, 38,2% were insolvent. After therapy, 62% of subjects were in debt, with 40% to 85% who had to quit their work due to the disabling disease The financial impact which the authors named “Financial toxicity” go beyond socioeconomic factors and have called out the politicians to take action. In a previous report (# 34) we had raised the question: Will there be an action on US drug pricing before year end?
A recent report by Vital Transformation, a consultancy group, suggests that the implementation of the proposed Lower Drugs Costs Now Act H.R.3 sponsored by US House Speaker Nancy Pelosi may cut revenue by more than half for companies affected medicine and the report goes as far as claiming that the plan could results in at least 56 fewer medicines over 10 years. The report which was commissioned by BIO, the Pharmaceutical Research Manufacturers of America and the Council of State Bioscience Associations is clearly biased and does not consider discoveries made in Europe, Japan and even China and brought to the US. In our view, a more stringent drug pricing policy will not induce a significant decrease in new drug launches, but will certainly strongly affect the valuation of start-up and emerging biopharmaceutical companies when they are raising funds or filing for an IPO.
In a statement made by Democratic Presidential candidate Elisabeth Warren, she now also proposes using compulsory licensing and antitrust actions to break biopharmaceutical control of drug pricing and she has already targeted a list of blockbusters.
More surprisingly, the ongoing clash between Health and Human Services (HHS) Secretary Alex Azar and Medicare Chief Seema Verma has shaken up parts of President Donald Trump’s own agenda, going as far as reversing his previous position to importing cheaper drugs from Canada (see Special Report# 34). Azar, who fully supports the traditional sceptical view of Republicans on controlling drug pricing dismissed the proposal in calling it “a gimmick”.
Undoubtedly pricing of drugs will be high on the list of all 2020 US Presidential candidates’ agenda. They would be well advised to benchmark overall healthcare performance in other highly developed countries when proposing reforms.
November 29,2019
This document has been prepared by btobioinnovation and is provided to you for information purposes only. The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change. btobioinnovation has no obligation to update its opinions or the information in this document.
Last News
- Note de réflexion de fin d’année
- EMA re-examines its opinion and approves Leqembi for the treatment of Alzheimer’s disease
- Le déclassement de la France
Events
News archives
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- March 2024
- February 2024
- January 2024
- November 2023
- September 2023
- July 2023
- April 2023
- March 2023
- January 2023
- December 2022
- November 2022
- October 2022
- August 2022
- June 2022
- May 2022
- April 2022
- March 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- October 2018
- June 2018
- May 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- September 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- June 2014
- May 2014
- April 2014
- March 2014
- January 2014
- November 2013
- September 2013
- July 2013
- May 2013
- April 2013
- March 2013
- January 2013
- December 2012
- November 2012
- October 2012
- March 2012